The applications of anti-CD20 antibodies to treat various B cells disorders

Zahra Payandeh; Armina Alagheband Bahrami; Reyhaneh Hoseinpoor; Yousef Mortazavi; Masoumeh Rajabibazl; Azam Rahimpour; Amir Hossein Taromchi; Saeed Khalil

Biomedicine & Pharmacotherapy (Jan 2019)

The applications of anti-CD20 antibodies to treat various B cells disorders

Zahra Payandeh,
Armina Alagheband Bahrami,
Reyhaneh Hoseinpoor,
Yousef Mortazavi,
Masoumeh Rajabibazl,
Azam Rahimpour,
Amir Hossein Taromchi,
Saeed Khalil

Affiliations

Zahra Payandeh: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Armina Alagheband Bahrami: Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Reyhaneh Hoseinpoor: Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Yousef Mortazavi: Cancer Gene Therapy Research Center, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; Corresponding author at: Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Masoumeh Rajabibazl: Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author at: Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Azam Rahimpour: Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Amir Hossein Taromchi: Cancer Gene Therapy Research Center, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
Saeed Khalil: Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran

Journal volume & issue: Vol. 109
pp. 2415 – 2426

Abstract

Read online

B-lymphocyte antigen CD20 (called CD20) is known as an activated-glycosylated phosphoprotein which is expressed on the surface of all B-cells. CD20 is involved in the regulation of trans-membrane Ca2+ conductance and also play critical roles in cell‐cycle progression during human B cell proliferation and activation. The appearance of monoclonal antibody (mAb) technology provided an effective field for targeted therapy in treatment of a variety of diseases such as cancer, and autoimmune diseases. Anti-CD20 is one of important antibodies which could be employed in treatment of several diseases. Increasing evidences revealed that efficacy of different anti-CD20 antibodies is implicated by their function. Hence, evaluation of anti-CD20 antibodies function could provide and introduce new anti-CD20 based therapies. In the present study, we summarized several applications of anti-CD20 antibodies in various immune related disorders including B-CLL (B-cell chronic lymphocytic leukemia), rheumatoid arthritis (RA), multiple sclerosis (MS) and melanoma.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords